This pathway was subsequently further elucidated in T1DAL [Inducing Remission in Type 1 Diabetes with Alefacept (4)], in which a comparable group of T1D subjects received alefacept, a LFA3-Ig fusion protein targeting CD2. The gene discussed is CD2; the disease is type 1 diabetes mellitus.